Park Avenue Securities LLC Raises Position in Takeda Pharmaceutical Co. $TAK

Park Avenue Securities LLC raised its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 8.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,363 shares of the company’s stock after purchasing an additional 2,535 shares during the period. Park Avenue Securities LLC’s holdings in Takeda Pharmaceutical were worth $531,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Farther Finance Advisors LLC raised its position in Takeda Pharmaceutical by 21.7% during the second quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock valued at $87,000 after purchasing an additional 1,003 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Takeda Pharmaceutical by 1.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 67,649 shares of the company’s stock valued at $1,038,000 after purchasing an additional 1,174 shares during the period. Sivia Capital Partners LLC purchased a new stake in Takeda Pharmaceutical during the second quarter valued at approximately $351,000. Intelligence Driven Advisers LLC raised its position in Takeda Pharmaceutical by 7.2% during the second quarter. Intelligence Driven Advisers LLC now owns 14,535 shares of the company’s stock valued at $225,000 after purchasing an additional 977 shares during the period. Finally, Aaron Wealth Advisors LLC raised its position in Takeda Pharmaceutical by 28.1% during the second quarter. Aaron Wealth Advisors LLC now owns 31,267 shares of the company’s stock valued at $483,000 after purchasing an additional 6,868 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold”.

Takeda Pharmaceutical Trading Up 0.6%

Shares of NYSE TAK opened at $14.74 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The business’s 50 day moving average price is $14.84 and its 200-day moving average price is $14.84. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.69. The company has a market cap of $46.90 billion, a price-to-earnings ratio of 49.13 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.